NEWTON, Mass.& PETACH TIKVA, Israel---- CyberArk, the global leader in identity security, today announced that it will report its second quarter 2025 financial results before the U.S. financial ...

CyberArk (CYBR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CyberArk CYBR reported strong subscription growth in the first quarter of fiscal 2025. Subscription annual recurring revenues (ARR) crossed $1.03 billion, up 65% from a year ago. Net new ...

CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it will report its second quarter 2025 ...

CyberArk (CYBR) Outpaces Stock Market Gains: What You Should Know June 26, 2025 — 06:00 pm EDT Written by Zacks Equity Research for Zacks -> ...

Why CyberArk (CYBR) Dipped More Than Broader Market Today June 20, 2025 — 06:00 pm EDT Written by Zacks Equity Research for Zacks -> ...

CyberArk (CYBR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

CyberArk CYBR is gaining traction in the fast-growing machine identity market. CyberArk’s acquisition of Venafi, a leader in machine identity management, is emerging as a key growth catalyst. In ...

CyberArk Software CYBR shares have gained 10.7% in the past month, outperforming the Zacks Security industry and its peers, including Palo Alto Networks PANW, Fortinet FTNT and SentinelOne S.

A month has gone by since the last earnings report for CyberArk (CYBR). Shares have added about 11.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

CyberArk is strengthening its identity security edge with AI-powered tools like CORA AI and Secure AI Agents.

Based on the average brokerage recommendation (ABR), CyberArk (CYBR) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of ...